This is a preview of subscription content, log in via an institution to check access.
Notes
Chinese renminbi
Reference
Yang L, et al. Economic Evaluation of Sevelamer versus Calcium-Based Binders in Treating Hyperphosphatemia among Patients with End-Stage Renal Disease in China. Clinical Therapeutics : 14 Oct 2016. Available from: URL: http://dx.doi.org/10.1016/j.clinthera.2016.09.012
Rights and permissions
About this article
Cite this article
Sevelamer cost effective for ESRD hyperphosphatemia in China. PharmacoEcon Outcomes News 765, 27 (2016). https://doi.org/10.1007/s40274-016-3512-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3512-4